cinnarizine (Stugeron) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cinnarizine is an antihistamine and calcium channel blocker of the diphenylmethylpiperazine group. It is prescribed for nausea and vomiting due to motion sickness or other sources such as chemotherapy, vertigo, or Ménière's disease.   Wikipedia

Chemistry

  • SMILES: C(\C=C\c1ccccc1)N2CCN(CC2)C(c3ccccc3)c4ccccc4
  • InChIKey: DERZBLKQOCDDDZ-JLHYYAGUSA-N
  • Mol. Mass: 368.52
  • ALogP: 5.11
  • ChEMBL Molecule:
    cinnarizine  
More Chemistry

Pharmacology

Alternative names

1-benzhydryl-4-cinnamylpiperazin | 1-cinnamyl-4-(diphenylmethyl)piperazine | 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine | 516 md | cinaperazine | cinarizina | cinarizine | cinnarizin | cinnarizine | cinnarizinum | cinnipirine | marzine r.f. | mylan travel sickness | r-1575 | r-516 | stugeron | stugeron fte | stunarone | stutgin

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Nausea

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Methamphetamine (Phase 4)

Nausea ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue